169 related articles for article (PubMed ID: 38078799)
21. Regulation of H2A ubiquitination and SLC7A11 expression by BAP1 and PRC1.
Zhang Y; Koppula P; Gan B
Cell Cycle; 2019 Apr; 18(8):773-783. PubMed ID: 30907299
[TBL] [Abstract][Full Text] [Related]
22. Glial Glutamate Transporter-Mediated Plasticity: System x
Dahlmanns M; Dahlmanns JK; Savaskan N; Steiner HH; Yakubov E
Front Biosci (Landmark Ed); 2023 Mar; 28(3):57. PubMed ID: 37005761
[TBL] [Abstract][Full Text] [Related]
23. Simple Fluorescence Assay for Cystine Uptake via the xCT in Cells Using Selenocystine and a Fluorescent Probe.
Shimomura T; Hirakawa N; Ohuchi Y; Ishiyama M; Shiga M; Ueno Y
ACS Sens; 2021 Jun; 6(6):2125-2128. PubMed ID: 34080411
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis.
Dixon SJ; Patel DN; Welsch M; Skouta R; Lee ED; Hayano M; Thomas AG; Gleason CE; Tatonetti NP; Slusher BS; Stockwell BR
Elife; 2014 May; 3():e02523. PubMed ID: 24844246
[TBL] [Abstract][Full Text] [Related]
25. Cystine/glutamate antiporter xCT controls skeletal muscle glutathione redox, bioenergetics and differentiation.
Kanaan MN; Pileggi CA; Karam CY; Kennedy LS; Fong-McMaster C; Cuperlovic-Culf M; Harper ME
Redox Biol; 2024 Jul; 73():103213. PubMed ID: 38815331
[TBL] [Abstract][Full Text] [Related]
26. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance.
Huang Y; Dai Z; Barbacioru C; Sadée W
Cancer Res; 2005 Aug; 65(16):7446-54. PubMed ID: 16103098
[TBL] [Abstract][Full Text] [Related]
27. ROS Mediate xCT-Dependent Cell Death in Human Breast Cancer Cells under Glucose Deprivation.
Chen MC; Hsu LL; Wang SF; Hsu CY; Lee HC; Tseng LM
Cells; 2020 Jul; 9(7):. PubMed ID: 32630312
[TBL] [Abstract][Full Text] [Related]
28. The Role of Cystine/Glutamate Antiporter SLC7A11/xCT in the Pathophysiology of Cancer.
Jyotsana N; Ta KT; DelGiorno KE
Front Oncol; 2022; 12():858462. PubMed ID: 35280777
[TBL] [Abstract][Full Text] [Related]
29. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
Roh JL; Kim EH; Jang HJ; Park JY; Shin D
Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
[TBL] [Abstract][Full Text] [Related]
30. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells.
Hasegawa M; Takahashi H; Rajabi H; Alam M; Suzuki Y; Yin L; Tagde A; Maeda T; Hiraki M; Sukhatme VP; Kufe D
Oncotarget; 2016 Mar; 7(11):11756-69. PubMed ID: 26930718
[TBL] [Abstract][Full Text] [Related]
31. The amino acid transporter SLC7A11-mediated crosstalk implicated in cancer therapy and the tumor microenvironment.
He J; Wang X; Chen K; Zhang M; Wang J
Biochem Pharmacol; 2022 Nov; 205():115241. PubMed ID: 36084707
[TBL] [Abstract][Full Text] [Related]
32. NADPH debt drives redox bankruptcy: SLC7A11/xCT-mediated cystine uptake as a double-edged sword in cellular redox regulation.
Liu X; Zhang Y; Zhuang L; Olszewski K; Gan B
Genes Dis; 2021 Nov; 8(6):731-745. PubMed ID: 34522704
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the effects of polyunsaturated fatty acids on transporter expressions using a PCR array: Induction of xCT/SLC7A11 in human placental BeWo cells.
Ono K; Furugen A; Kurosawa Y; Jinno N; Narumi K; Kobayashi M; Iseki K
Placenta; 2019 Jan; 75():34-41. PubMed ID: 30712664
[TBL] [Abstract][Full Text] [Related]
34. xCT (SLC7A11) expression confers intrinsic resistance to physical plasma treatment in tumor cells.
Bekeschus S; Eisenmann S; Sagwal SK; Bodnar Y; Moritz J; Poschkamp B; Stoffels I; Emmert S; Madesh M; Weltmann KD; von Woedtke T; Gandhirajan RK
Redox Biol; 2020 Feb; 30():101423. PubMed ID: 31931281
[TBL] [Abstract][Full Text] [Related]
35. TGF-β1-mediated repression of SLC7A11 drives vulnerability to GPX4 inhibition in hepatocellular carcinoma cells.
Kim DH; Kim WD; Kim SK; Moon DH; Lee SJ
Cell Death Dis; 2020 May; 11(5):406. PubMed ID: 32471991
[TBL] [Abstract][Full Text] [Related]
36. Hyperexcitability and brain morphological differences in mice lacking the cystine/glutamate antiporter, system x
Sears SMS; Roberts SH; Hewett SJ
J Neurosci Res; 2021 Dec; 99(12):3339-3353. PubMed ID: 34747522
[TBL] [Abstract][Full Text] [Related]
37. xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression.
Ji X; Qian J; Rahman SMJ; Siska PJ; Zou Y; Harris BK; Hoeksema MD; Trenary IA; Heidi C; Eisenberg R; Rathmell JC; Young JD; Massion PP
Oncogene; 2018 Sep; 37(36):5007-5019. PubMed ID: 29789716
[TBL] [Abstract][Full Text] [Related]
38. Regulation of system x(c)(-)activity and expression in astrocytes by interleukin-1β: implications for hypoxic neuronal injury.
Jackman NA; Uliasz TF; Hewett JA; Hewett SJ
Glia; 2010 Nov; 58(15):1806-15. PubMed ID: 20645408
[TBL] [Abstract][Full Text] [Related]
39. EZH2-mediated SLC7A11 upregulation via miR-125b-5p represses ferroptosis of TSCC.
Yu Y; MohamedAl-Sharani H; Zhang B
Oral Dis; 2023 Apr; 29(3):880-891. PubMed ID: 34614259
[TBL] [Abstract][Full Text] [Related]
40. Genetic Ablation of the Cystine Transporter xCT in PDAC Cells Inhibits mTORC1, Growth, Survival, and Tumor Formation via Nutrient and Oxidative Stresses.
Daher B; Parks SK; Durivault J; Cormerais Y; Baidarjad H; Tambutte E; Pouysségur J; Vučetić M
Cancer Res; 2019 Aug; 79(15):3877-3890. PubMed ID: 31175120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
